Synaptogenix IncNASDAQ SNPX Stock Report

Synaptogenix, Inc., formerly Neurotrope BioScience, Inc. is a biopharmaceutical company. The Company is principally focused on developing therapeutics for patients with neurodegenerative diseases and developmental disorders. The Company is developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD). Its lead product candidate is bryostatin-1. Bryostatin-1 is a Protein Kinase C Epsilon (PKC e), a and e activator that was originally developed as a potential anticancer drug. The Company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.